Daily Stock Setups

ProtoKinetix' AAGP(TM) is Critical for Stem Cell Therapy

Posted on: Thu, 19 Feb 2009 07:30:00 EST

Symbols: PKTX

Are you looking to increase your ETF knowledge?

VANCOUVER, Feb 19, 2009 (BUSINESS WIRE) --
PKTX | Quote | Chart | News | PowerRating -- Protokinetix' (PKTX) results over the last 2-years have clearly shown
the vital role that AAGP(TM) can play in this exciting disease treatment
arena. Support for stem cell research has never been stronger and
continues to grow. This growth will accelerate as successful results are
announced.

One of the most important ingredients for the success of this therapy is
the recovery of the maximum number of viable stem cells after storage.
These extremely delicate cells typically have a very low yield after
cryopreservation. AAGP(TM) testing that has been conducted on stem cell
preservation at all temperatures has shown an impressive increase in
survivability and viability.

In summary, over the past 24-months, AAGP(TM) has demonstrated a remarkable
increase in viable cell recovery at temperatures ranging from -196EsC
(cryopreservation) all the way to 37EsC (body temperature). These results
have been consistent regardless of the source of the stem cells. As an
example, AAGP(TM) has been independently tested as a protective agent in
the cryopreservation (-196EsC) and subsequent thawing of umbilical cord
blood in low concentrations of AAGP(TM) (4mg/ml). The resultant analysis
revealed a more than double average increase over the control group
(cells not protected with AAGP(TM)) in the yield, following thawing.

About ProtoKinetix

ProtoKinetix Inc. is a biotechnology company that has developed and
patented a family of synthetic anti-aging glycopeptides (AAGP(TM)) for
medicine and the biotechnology and cosmetic industries. PKTX is
currently in dialog with major corporations and institutions who have
contacted the Company about the broad range of applications for AAGP(TM)
products. For more detailed information, visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Some information included in
this press release contains statements that are forward-looking. Such
forward-looking information involves significant risks and uncertainties
that could affect anticipated results in the future and, accordingly,
these results may differ materially from those expressed in any
forward-looking statements made by or on behalf of the Company. For a
description of additional risks and uncertainties, please refer to the
Company's filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO

SOURCE: PROTOKINETIX INC.

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887

For full details on (PKTX) PKTX. (PKTX) has Short Term PowerRatings at TradingMarkets. Details on (PKTX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.